Drug development research agreement leverages simulation platform

By Maggie Lynch

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags Research Simulation Drug development Drug development process Translational medicine Biology Antibody drug conjugates

Drug development advisory firm Rosa & Co. enters research agreement with Chugai pharmaceutical to provide access to PhysioPD research services for translational biology.

Chugai, a member of the Roche group, will receive access to Rosa’s research and development services, PhysioPD, a quantitative systems pharmacology approach to translate biology into an interactive simulation platform. The approach translates biology into an interactive simulation platform to represent physiology, disease, and intervention effects.

Per the collaboration, Chugai will use this service across multiple therapeutic areas on its research and development pipeline to discover actionable program recommendations to reduce risk and address consequential decisions regarding drug development.

Rosa and Chugai have engaged in projects together in the past. “We are extremely pleased to extend our relationship with Chugai. Over the last several years we have been working with them on various projects and this agreement validates the value PhysioPD Research brings,”​ Ron Beaver, founder and CEO of Rosa, said in a statement.

Chugai launched the first antibody-drug created in Japan in the 1990s and is currently focused on its proprietary antibody engineering technologies for antibody drug development.

Kimio Terao, department manager of clinical pharmacology and translational research at Chugai, said in a statement, “Chugai strives to develop hand in hand with society through the creation of innovative drugs and services. I am convinced that Rosa's novel platform will provide a powerful tool to transform our research into real innovation.”

Related news

Related products

show more

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Content provided by Elligo Health Research® | 13-Apr-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more